TransForm was founded in late 1999 with initial technology licensed from Millennium Pharmaceuticals (NASDAQ:MLNM). The two co-founders, Nicholas Galakatos, PhD, and Robert Langer, PhD, bring many years of experience in building successful and innovative companies in drug discovery and delivery.
Dr. Langer is the Germeshausen Professor of Chemical Engineering and Biomedical Engineering at MIT, a world authority in the field of drug delivery, the only active member of all three National Academies (Sciences, Engineering and Medicines), former Chairman of the FDA Science Advisory Board, and a co-founder and Board member of several biotechnology companies. He remains an active member of TransForm’s Board of Directors.
Dr. Galakatos, currently Chairman of the Board of TransForm, is a General Partner at MPM Capital, the world’s largest healthcare venture capital firm, and has been a co-founder and/or founding investor of several biotechnology companies.
TransForm, a private company, has raised over $50 million from leading healthcare investors including MPM Capital, Polaris Venture Partners, Lombard-Odier, Schweizerhall, HBM BioVentures, Eli Lilly and Company, Novartis BioVentures, SG Cowen, and other financial and strategic investors.